Ocugen, Inc., a privately held clinical-stage biopharmaceutical company, has acquired Histogenics Corporation (NASDAQ: HSGX). Although no financial terms were disclosed, the merged company will be publicly-traded, operating under the Ocugen name.
Ocugen discovers, develops and commercializes a pipeline of innovative therapies that address rare and underserved eye diseases. Histogenics develops a restorative cell therapy technology platform. It has collaborated with Brigham and Women’s Hospital, Cornell University and other leading institutions to advance molecular biology and proprietary materials sciences.
Perhaps a big factor driving Ocugen’s purchase is Histogenic’s pipeline in areas such as cell restorative therapy and its NeoCart platform, a Phase 3 investigational product that uses bio-engineering and cell processing for orthopedic use.
This is not the only deal to focus on cell therapies in the biotech world this week. Shanghai Fosun Pharmaceutical bought an exclusive license to develop, manufacture, and commercialize CTX and hRPC cell therapy programs in China from ReNeuron for $7.9 million and nearly $18.5 million in milestones.
